MedTrace Logo

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

NCT00606814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-03-06

No results posted yet for this study

Summary

This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine:

* the safety profile,
* the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and
* to recommend a Phase II dose of the combination in patients with solid tumors.

Conditions

Interventions

DRUG

IPI-504, docetaxel

1. IPI-504 administered IV at a dose of 300mg/m2 2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration

Sponsors & Collaborators

  • Infinity Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Gregory Riely, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-05-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606814 on ClinicalTrials.gov